- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03710850
Modification of Gut Microbiota in the Treatment of Insulin Resistance: a Personalized Approach (TRIEMA)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The aim of this project is to study the possibilities of gut microbiota manipulation in type 2 diabetes (T2D) towards more beneficial genetic and metabolic profile. This study address several issues. First, identification of specific metagenome/metabolome features characteristic for human cohorts with different risk of T2D development. Second, the resilience of microbiota associated with beneficial metabolic phenotype in pro-diabetogenic environment and the possibility to support its survival by prebiotic treatment. Third, development of the method for personalized prediction of the effectivity of prebiotic treatment in T2D patients and the evaluation of the benefit of long-term prebiotic administration in responders´ subpopulation. The project will be realized in three work packages.
WP1: Observation study focused on the description of gut microbiome and metabolome in obese type 2 diabetics, vegans and obese but otherwise healthy omnivores and identification of key markers specific for these populations.
WP2: Study focused on the interaction of vegan microbiota and pro-diabetogenic (western-type) diet and on the effects of prebiotic supplementation in germ-free animals. In addition, the effect of diet-alone and the effect of standardized Schaedler flora will be tested as well.
WP3: The identification of predictive markers indicative for the benefit of prebiotic treatment in the individual context (T2D cohort) and second, long-term human intervention study in the selected responders´ group aimed on the possibility of therapeutic modulation of gut microbiome/ metabolome by prebiotics. Only WP3 is subjected to clinical trial registration.
In details:
WP 3: Identification of T2D subpopulations according to their susceptibility to dietary fiber intervention Questions:
- Are there different subpopulations within T2D subjects that differ in their ability to increase SCFA production in response to prebiotic supplementation?
- Is it possible to identify these subpopulations ("responders" vs "non-responders") by simple intervention test?
- Is this phenomenon associated with specific microbiota composition?
- Within "responder" subpopulation, is it possible to manipulate fecal metabolome/metagenome towards more beneficial composition by long-term prebiotic intervention? In order to fulfill this task microbiome characterization of T2D cohort in WP1 will be used.
The aim of WP3 is to provide the proof of concept that a diet enriched with specific prebiotics improves the specific (SCFA) metabolite production and that the beneficial effect is dependent on pre-existing microbiota composition.
Acute intervention test ("inulin test") The participants enrolled into T2D cohort will be asked to participate in short-term intervention test. They will be provided the prebiotic and instructed on the test procedure.
Step 1: sample the stool ("sample 1"); step 2: take the dose (20 g) of inulin; step 3: during following three days collect sample of feces at each defecation. The samples will be analyzed by NMR and mass spectrometry with special respect to SCFA content.
Primary readout: The magnitude of SCFA content elevation after the bolus prebiotic administration.
Secondary readout: The potential association between the response to prebiotic bolus and microbiota composition.
Long-term intervention study Based on the results of acute inulin intervention test, the subgroups of most pronounced "responders" and "non-responders" will be selected (defined as both extreme tertiles of the group, at least 10 subjects are expected to be enrolled per subgroup). Participants from both subgroups will be asked to take part in three months intervention study when they will be administered 10 g of inulin prebiotic (FAN s.r.o., Tišice 225, 27715 Tišice) on every-day basis. Prior and at the end of the intervention period, the participants will be subjected to metabolic characterization, indirect calorimetry and assessment of intestine permeability. Feces samples will be collected before the study and then after each month for 16S rRNA sequencing, NMR spectroscopy and mass spectrometry.
Primary readout:
gut microbiome and fecal, urine and plasma metabolome composition of feces
Secondary readouts:
- metabolic characteristics: basal blood tests (glucose, lipid profile, NEFA, insulin, C-peptide); twostep hyperinsulinemic euglycemic clamp; indirect calorimetry with energy expenditure and respiratory quotient
- intestinal permeability markers: serum content of bacterial endotoxin, D-lactate, endotoxin core antibody, iFABP and citrulline.
Expected outcome: validation of short prebiotic intervention test as a tool for prediction of the efficiency and benefit of long-term prebiotic supplementation; evaluation of the benefit of long-term prebiotic supplementation in T2D "responder" subgroup.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Prague, Czechia, 10084
- University Hospital Kralovske Vinohrady
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- overweight or obese volunteers (BMI over 25)
Exclusion Criteria:
- diabetes on medication
- any disease known to affect intestinal permeability
- antibiotic use less than 3 months prior to enrollment
- gravidity/lactation in women
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Responders
Responders in terms of fecal butyrate production after acute inulin test.
|
Inulin is a dietary fibre.
Will be supplemented in a dose 10g/d for a period of 3 moths.
|
Experimental: Non-responders
Non-responders in terms of fecal butyrate production after acute inulin test.
|
Inulin is a dietary fibre.
Will be supplemented in a dose 10g/d for a period of 3 moths.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Butyrate production
Time Frame: 3 months
|
Fecal butyrate content
|
3 months
|
Glucose disposal
Time Frame: 3 months
|
Rate of glucose disposal from 80IU insulin glucose clamp
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Suppression of lipolysis
Time Frame: 3 months
|
Decrease in plasma levels of glycerol/NEFA in 10IU insulin glucose clamp
|
3 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Jan Gojda, MD, PhD, Third Faculty of Medicine Charles University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- NV18-01-00040
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Insulin Resistance
-
Washington University School of MedicineNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National...CompletedEndoplasmic Reticulum Stress | HIV Related Insulin Resistance | Protease Inhibitor Related Insulin ResistanceUnited States
-
Paloma Almeda-ValdésCompleted
-
German Diabetes CenterYale UniversityRecruiting
-
National Institute of Diabetes and Digestive and...Active, not recruitingSevere Insulin ResistanceUnited States
-
Eunice Kennedy Shriver National Institute of Child...Completed
-
Assiut UniversityCompleted
-
National Taiwan UniversityNational Cheng-Kung University HospitalCompletedExercise, Insulin Resistance, Visceral Adipose TissueTaiwan
-
University Health Network, TorontoCompletedInsulin Resistance Syndrome X | Pancreatic Beta Cell FunctionCanada
-
The University of Texas Medical Branch, GalvestonCompletedInsulin Resistance, DiabetesUnited States
-
University Health Network, TorontoCompletedInsulin Resistance, DiabetesCanada
Clinical Trials on Inulin
-
Scottish Universities Environmental Research CentreUniversity of Glasgow; NHS Greater Clyde and GlasgowCompletedObesity | OverweightUnited Kingdom
-
Eskisehir Osmangazi UniversityUnknownFunctional Constipation
-
Maastricht University Medical CenterCompleted
-
Imperial College LondonUniversity of GlasgowCompletedAppetite Regulation | Healthy Obesity, MetabolicallyUnited Kingdom
-
University of Illinois at Urbana-ChampaignRenal Research InstituteCompletedBone Diseases, Endocrine | Nutritional and Metabolic DiseasesUnited States
-
Augusta UniversityAmerican Gastroenterological Association FoundationCompletedInvestigation of Dietary Absorptive Capacity of Fructans in Healthy Subjects - A Dose Response StudyHealthy VolunteersUnited States
-
University of ReadingUnknownOverweight and ObesityUnited Kingdom
-
Second Xiangya Hospital of Central South UniversityNot yet recruitingType 1 Diabetes Mellitus | Autoimmune DiabetesChina
-
National Institute of Diabetes and Digestive and...University of Pennsylvania; George Washington UniversityUnknownChronic Kidney DiseasesUnited States
-
CindetecNucitec SA de CVCompleted